Business & Finance India's Panacea Biotec to produce 100mn Sputnik V doses annually: RDIF Panacea Biotec Ltd has agreed to produce 100 million doses of Russia's Sputnik V COVID-19 vaccine annually. Published April 5, 2021 Updated April 5, 2021 06:04pm Save Saved 1 min Comments By Reuters Add BRecorder as a trusted source on Google MOSCOW: Indian biotech firm Panacea Biotec Ltd has agreed to produce 100 million doses of Russia's Sputnik V COVID-19 vaccine annually, the Russian Direct Investment Fund (RDIF), which markets the shot internationally, said on Monday. RDIF did not say when production would begin. Russia's Sputnik V vaccine Comments Comments are closed for this article. More Stories Pakistan seeks $10bn in US backstop facility to boost reserves Aurangzeb seeks US support for Pakistan in Bessent meeting Negative sentiments drive selling at PSX, KSE-100 down 1,800 points Pakistan courts Samsung for smartphone exports as tech giant seeks tariff support Petroleum dealers divided over nationwide shutdown Gold per tola gains Rs4,600 in Pakistan War in Iran has cost the US $37.5 billion so far, Pentagon says Hormuz vessel crossings fall further as security concerns linger Oil prices rise slightly after US announces new round of strikes on Iran UBL unveils Rs40bn strategic investment plan Rubio says US still willing to negotiate over Iran crisis Browse all stories
Comments
Comments are closed for this article.